Treatment with the GPR55 antagonist CID16020046 increases neutrophil activation in mouse atherogenesis

Thrombosis and Haemostasis

Volumn 116, Issue 5, 2016, Pages 987-997

  Montecucco, Fabrizio ^a,b   Bondarenko, Alexander I ^c   Lenglet, Sébastien ^d   Burger, Fabienne ^d   Piscitelli, Fabiana ^e   Carbone, Federico ^a   Roth, Aline ^d   Liberale, Luca ^a   Dallegri, Franco ^a   Brandt, Karim J ^d   Fraga Silva, Rodrigo A ^f   Stergiopulos, Nikolaos ^f   Di Marzo, Vincenzo ^e   Mach, François ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c BOGOMOLETZ INSTITUTE OF PHYSIOLOGY   (Ukraine)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e CNR   (Italy)

^f EPFL   (Switzerland)

Author keywords

Atherosclerosis; Endocannabinoids; Neutrophil; Receptors

Indexed keywords

4 [4 (3 HYDROXYPHENYL) 3 (4 METHYLPHENYL) 6 OXO 1 H,4 H,5 H,6 H PYRROLO[3,4 C]PYRAZOL 5 YL] BENZOIC ACID; BENZOIC ACID DERIVATIVE; CHOLESTEROL; COLLAGEN; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; ENDOCANNABINOID; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 4-(4-(3-HYDROXYPHENYL)-3-(4-METHYLPHENYL)-6-OXO-1H,4H,5H,6H-PYRROLO(3,4-C)PYRAZOL-5-YL)BENZOIC ACID; AZABICYCLO DERIVATIVE; CANNABINOID RECEPTOR; CXCL2 PROTEIN, MOUSE; GELATINASE B; GPR55 PROTEIN, MOUSE; MMP9 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CELL MIGRATION ASSAY; CHEMOTAXIS; CONTROLLED STUDY; DEGRANULATION ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUTHANASIA; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; LEUKOCYTE ACTIVATION; LIMULUS LYSATE TEST; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; APOLIPOPROTEIN E KNOCKOUT MOUSE; ATHEROSCLEROSIS; METABOLISM;

ANIMALS; ATHEROSCLEROSIS; AZABICYCLO COMPOUNDS; BENZOATES; CHEMOKINE CXCL2; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT, APOE; NEUTROPHIL ACTIVATION; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, CANNABINOID;

EID: 84994607981     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-02-0139     Document Type: Article

References (39)

1. Ouweneel AB, Van Eck M. Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulation. Vascul Pharmacol 2015; doi: 10.1016/j.vph.2015.10.009.
2. Ketelhuth DF, Hansson GK. Cellular immunity, low-density lipoprotein and atherosclerosis: break of tolerance in the artery wall. Thromb Haemost 2011; 106: 779-786.
3. Ray KK, Kastelein JJ, Boekholdt SM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014; 35: 960-968.
4. Montecucco F, Di Marzo V. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci 2012; 33: 331-340.
5. Li YF, Li RS, Samuel SB, et al. Lysophospholipids and their G protein-coupled receptors in atherosclerosis. Front Biosci 2016; 21: 70-88.
6. Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434: 782-786.
7. Quercioli A, Pataky Z, Vincenti G, et al. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J 2011; 32: 1369-1378.
8. Stancic A, Jandl K, Hasenöhrl C, et al. The GPR55 antagonist CID16020046 protects against intestinal inflammation. Neurogastroenterol Motil 2015; 27: 1432-1445.
9. Oka S, Nakajima K, Yamashita A, et al. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 2007; 362: 928-934.
10. Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092-1101.
11. Lauckner JE, Jensen JB, Chen HY, et al. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 2008; 105: 2699-2704.
12. Zhao P, Abood ME. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. Life Sci 2013; 92: 453-457.
13. Piñeiro R, Falasca M. Lysophosphatidylinositol signalling: new wine from an old bottle. Biochim Biophys Acta 2012; 1821: 694-705.
14. AlSuleimani YM, Hiley CR. The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells. Br J Pharmacol 2015; 172: 3043-3057.
15. Chiurchiù V, Lanuti M, De Bardi M, et al. The differential characterization of GPR55 receptor in human peripheral blood reveals a distinctive expression in monocytes and NK cells and a proinflammatory role in these innate cells. Int Immunol 2015; 27: 153-160.
16. Balenga NA, Aflaki E, Kargl J, et al. GPR55 regulates cannabinoid 2 receptormediated responses in human neutrophils. Cell Res 2011; 21: 1452-1469.
17. Hiley CR, Kaup SS. GPR55 and the vascular receptors for cannabinoids. Br J Pharmacol 2007; 152: 559-561.
18. Lanuti M, Talamonti E, Maccarrone M, et al. Activation of GPR55 Receptors Exacerbates oxLDL-Induced Lipid Accumulation and Inflammatory Responses, while Reducing Cholesterol Efflux from Human Macrophages. PLoS One 2015; 10: e0126839.
19. Borrelli F, Romano B, Petrosino S, et al. Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. Br J Pharmacol 2015; 172: 142-158.
20. Li K, Feng JY, Li YY, et al. Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice. Pancreas 2013; 42: 123-129.
21. Schicho R, Bashashati M, Bawa M, et al. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis 2011; 17: 1651-1664.
22. Al Suleimani YM, Al Mahruqi AS, Hiley CR. Mechanisms of vasorelaxation induced by the cannabidiol analogue compound O-1602 in the rat small mesenteric artery. Eur J Pharmacol 2015; 765: 107-114.
23. Montecucco F, Lenglet S, Carbone F, et al. Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response. Vascul Pharmacol 2015; 72: 197-208.
24. Montecucco F, Vuilleumier N, Pagano S, et al. Anti-Apolipoprotein A-1 autoantibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011; 32: 412-421.
25. Winnik S, Gaul DS, Preitner F, et al. Deletion of Sirt3 does not affect atherosclerosis but accelerates weight gain and impairs rapid metabolic adaptation in LDL receptor knockout mice: implications for cardiovascular risk factor development. Basic Res Cardiol 2014; 109: 399.
26. Seneviratne AN, Cole JE, Goddard ME, et al. Low shear stress induces M1 macrophage polarization in murine thin-cap atherosclerotic plaques. J Mol Cell Cardiol 2015; 89: 168-172.
27. Montecucco F, Di Marzo V, da Silva RF, et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 2012; 33: 846-856.
28. Montecucco F, Lenglet S, Braunersreuther V, et al. Single administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice. Arterioscler Thromb Vasc Biol 2010; 30: 1371-1377.
29. Lecut C, Frederix K, Johnson DM, et al. P2X1 ion channels promote neutrophil chemotaxis through Rho kinase activation. J Immunol 2009; 183: 2801-2809.
30. Matias I, Carta G, Murru E, et al. Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochim Biophys Acta 2008; 1781: 52-60.
31. Nencioni A, da Silva RF, Fraga-Silva RA, et al. Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. Thromb Haemost 2014; 111: 308-322.
32. Wiesner P, Choi SH, Almazan F, et al. Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activate macrophages via nuclear factor kappa B and activator protein-1: possible mechanism for acceleration of atherosclerosis by subclinical endotoxemia. Circ Res 2010; 107: 56-65.
33. Montecucco F, Matias I, Lenglet S, et al. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis 2009; 205: 433-441.
34. Wendorff C, Wendorff H, Pelisek J, et al. Carotid Plaque Morphology Is Significantly Associated With Sex, Age, and History of Neurological Symptoms. Stroke 2015; 46: 3213-3219.
35. Bot PT, Grundmann S, Goumans MJ, et al. Forkhead box protein P1 as a downstream target of transforming growth factor-β induces collagen synthesis and correlates with a more stable plaque phenotype. Atherosclerosis 2011; 218: 33-43.
36. Drechsler M, Megens RT, van Zandvoort M, et al. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010; 122: 1837-1845.
37. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res 2012; 110: 875-888.
38. Nguyen DH, Giri B, Collins G, et al. Dynamic reorganization of chemokine receptors, cholesterol, lipid rafts, and adhesion molecules to sites of CD4 engagement. Exp Cell Res 2005; 304: 559-569.
39. Balenga NA, Martínez-Pinilla E, Kargl J, et al. Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling. Br J Pharmacol 2014; 171: 5387-5406.